Squamous Cell Carcinoma: The Skin Cancer That Demands Respect

Squamous cell carcinoma (SCC) is the second most common form of skin cancer, arising from the squamous cells that make up the middle and outer layers of the epidermis. 8 million cases are diagnosed in the United States annually, and the incidence has been rising sharply — by some estimates increasing 200% over the past three decades due to aging populations, accumulated UV exposure, and increased detection. SCC occupies a critical middle ground in skin cancer severity: it is far more common and generally less aggressive than melanoma, but significantly more dangerous than basal cell carcinoma because of its genuine potential to metastasize.

When SCC spreads to regional lymph nodes or distant organs, the prognosis worsens dramatically — metastatic SCC carries a five-year survival rate of approximately 30-50%, depending on the extent of spread. The disease typically develops on sun-exposed skin — face, ears, scalp, neck, hands, and forearms — but can also arise on the lips, inside the mouth, on the genitals, and in areas of chronic scarring or inflammation. SCC often develops from precursor lesions, particularly actinic keratoses, making it one of the few cancers with a clearly identifiable pre-cancerous stage that offers a window for preventive intervention. The trajectory from normal skin to sun damage to actinic keratosis to invasive SCC illustrates why cumulative sun protection matters at every age and why treating pre-cancerous lesions prevents cancer development.

Cumulative ultraviolet radiation exposure is the dominant risk factor for SCC — unlike melanoma, which is associated with intense intermittent sun exposure and sunburns, SCC correlates more strongly with total lifetime UV dose. This makes SCC particularly common in outdoor workers, people living at lower latitudes, and those with decades of recreational sun exposure. Fair skin, light hair, and blue or green eyes confer the highest risk, but SCC occurs in all skin types.

In darker-skinned individuals, SCC more often develops in areas of chronic scarring, inflammation, or non-sun-exposed sites, and these SCCs tend to be more aggressive. Immunosuppression is a powerful risk multiplier: organ transplant recipients taking anti-rejection medications face a 65-250 times increased risk of SCC compared to the general population, and their SCCs are more aggressive and more likely to metastasize. HIV/AIDS, chronic lymphocytic leukemia, and other immunocompromising conditions similarly elevate risk.

Human papillomavirus (HPV) infection plays a role in SCC development, particularly on the genitals, perianal area, and in immunosuppressed individuals. Certain HPV types (16, 18) are directly carcinogenic to squamous cells. Chronic wounds, scars, and areas of chronic inflammation can give rise to SCC — Marjolin's ulcer describes SCC arising in a chronic wound or burn scar, often decades after the original injury.

Radiation therapy for other conditions increases SCC risk in the treated field. Exposure to arsenic, certain industrial chemicals, and coal tar derivatives elevates risk. A personal history of any skin cancer substantially increases SCC risk, as does a history of actinic keratoses.

Genetic conditions like xeroderma pigmentosum (impaired DNA repair) cause extreme susceptibility. Smoking is specifically associated with SCC of the lip.

Squamous cell carcinoma presents in several forms, and recognizing its varied appearances is essential for early detection. The most common presentation is a firm, red nodule, often with a rough, scaly, or crusted surface. Unlike the pearly, translucent quality of basal cell carcinoma, SCC tends to look thicker, rougher, and more opaque.

A flat lesion with a scaly, crusted surface that gradually enlarges is another common presentation, particularly on the trunk and extremities. SCC of the lip typically appears as a persistent rough, scaly, or ulcerated patch on the lower lip. The hallmark warning sign shared across SCC presentations is a sore that doesn't heal — a lesion that bleeds, crusts over, appears to improve, then breaks down again repeatedly over weeks to months.!!

Any non-healing wound on sun-exposed skin should be evaluated. SCC can also present as a wart-like growth, a horn-like projection of hard keratin (cutaneous horn), or an area of thickened, rough skin that bleeds when scales are removed. On the ear, SCC often appears as a tender, crusted nodule on the helix or antihelix.

On the scalp, it may present as a non-healing sore or an area of thickening in a bald or thinning area. Features that suggest higher risk include rapid growth, large size (greater than 2cm), location on the ear, lip, or temple, invasion into deeper structures (palpable fixation to underlying tissue), tenderness or pain, and perineural invasion symptoms such as numbness, tingling, or muscle weakness in the area. The transition from actinic keratosis to SCC can be subtle — an AK that becomes thicker, more tender, or develops a raised base may be progressing to invasive SCC and requires biopsy.

SCC staging determines treatment approach and predicts outcome. The American Joint Committee on Cancer (AJCC) staging system considers tumor size, depth of invasion, location, and pathological features. Stage I SCCs are localized tumors smaller than 2cm without high-risk features, with cure rates exceeding 95% with appropriate treatment.

Stage II tumors are larger than 2cm or have high-risk pathological features (poor differentiation, perineural invasion, depth beyond 6mm or into subcutaneous fat) but remain localized, with cure rates of 70-90%. Stage III indicates regional lymph node involvement, with five-year survival dropping to approximately 40-60%. Stage IV represents distant metastasis, carrying a five-year survival rate of roughly 20-30%.

High-risk features that worsen prognosis include tumor diameter greater than 2cm, depth exceeding 6mm or invasion beyond subcutaneous fat, perineural invasion (cancer growing along nerve sheaths, causing pain, numbness, or weakness), poor histologic differentiation, location on the ear or lip (which carry 2-3 times higher metastatic risk than other sites), immunosuppression, and recurrence after prior treatment. The metastatic rate for cutaneous SCC overall is approximately 2-5%, but for high-risk subgroups this rises substantially — SCC of the lip metastasizes in up to 14% of cases, and SCC in immunosuppressed patients metastasizes far more frequently. Understanding your specific risk profile guides treatment intensity: a small, well-differentiated SCC on the forearm may be adequately treated with standard excision, while a poorly differentiated SCC on the ear with perineural invasion requires Mohs surgery, possible adjuvant radiation, and close surveillance for metastasis.

Treatment options for SCC depend on tumor characteristics and risk stratification. Standard surgical excision with predetermined margins (4-6mm for low-risk tumors, wider for higher-risk lesions) is appropriate for many SCCs, providing cure rates above 92% for primary lesions. The specimen is sent for pathological examination to confirm clear margins.

Mohs micrographic surgery offers the highest cure rate (97-99% for primary SCC) and maximum tissue conservation by examining 100% of the surgical margin during the procedure. Mohs is particularly indicated for SCCs on the face, ears, lips, hands, and genitals; for large or aggressive tumors; for tumors with poorly defined borders; for recurrent SCCs; and for tumors in immunosuppressed patients. The ability to examine the entire surgical margin in real time, rather than sampling a fraction as in standard excision, accounts for Mohs' superior cure rate.

For patients who are not surgical candidates due to medical comorbidities, radiation therapy provides an effective alternative, achieving cure rates of 90% for small, primary SCCs. Radiation is also used as adjuvant treatment after surgery for high-risk features like perineural invasion or positive margins when re-excision isn't feasible. Curettage and electrodesiccation may be appropriate for small, low-risk SCCs in non-critical locations.

For advanced, unresectable, or metastatic SCC, systemic immunotherapy with checkpoint inhibitors has transformed the treatment landscape. Cemiplimab (Libtayo) and pembrolizumab (Keytruda) are approved for advanced cutaneous SCC and achieve response rates of approximately 40-50%, offering meaningful benefit for patients who previously had few options. Chemotherapy (cisplatin-based regimens) remains an option but is less effective and more toxic than immunotherapy.

Targeted therapy with EGFR inhibitors (cetuximab) provides another systemic option. For locally advanced SCC not amenable to surgery or radiation, multidisciplinary tumor board review ensures optimal treatment planning.

Any new or changing growth on sun-exposed skin deserves professional evaluation, but certain features demand urgent attention. A sore that won't heal after 3-4 weeks should be examined — persistent non-healing is the most common presenting symptom of SCC.!! Rapid growth of a skin lesion over days to weeks suggests an aggressive process requiring prompt biopsy.

' If you have a history of actinic keratoses and one becomes thicker, more painful, or develops a raised, indurated base, this may indicate progression to SCC. Any growth on the lip, ear, or temple that persists beyond a few weeks should be biopsied — these locations carry higher metastatic risk and warrant proactive evaluation. Numbness, tingling, or muscle weakness near a skin lesion suggests perineural invasion and requires urgent assessment.

Swollen lymph nodes near a skin cancer or previous skin cancer site demand immediate evaluation for metastasis. For immunosuppressed patients (organ transplant recipients, HIV-positive individuals, patients on immunosuppressive medications), any new skin growth warrants a lower threshold for biopsy due to the dramatically elevated SCC risk and more aggressive behavior in this population. If you've had a previous SCC, remain vigilant — the risk of developing additional SCCs is substantial, and early detection of new primaries or recurrence is essential.

Squamous cell carcinoma is highly curable when detected early but potentially life-threatening when diagnosed late. Skinscanner provides an accessible screening tool that can help identify suspicious lesions between professional skin examinations. Our AI has been trained to recognize the visual features associated with SCC — firm nodules with rough or crusted surfaces, non-healing sores, and the subtle changes that distinguish a developing cancer from a benign spot.

By photographing concerning lesions, you receive immediate analysis flagging features that warrant dermatologic evaluation. For those at high risk — fair-skinned individuals with extensive sun exposure, immunosuppressed patients, anyone with a history of skin cancer or actinic keratoses — regular scanning of sun-exposed areas creates a surveillance system that catches changes early. Monthly documentation of your skin allows you to detect the gradual enlargement, surface changes, or new lesion development that occurs slowly enough to escape casual observation but is readily apparent in side-by-side photographs taken weeks apart.

Skinscanner is especially valuable for monitoring known actinic keratoses, as the transition from pre-cancer to invasive SCC can be subtle — thickening, increased tenderness, or development of a raised base may be captured in photographic comparisons before you'd notice the change in daily life. For hard-to-see areas like the scalp, ears, and back where SCC commonly develops, having a partner photograph these areas for AI analysis fills a critical gap in self-examination. Skinscanner does not diagnose cancer — only biopsy can definitively establish an SCC diagnosis — but it provides the early alert that prompts you to seek the professional evaluation that could save your life.